UA73748C2 - Medicaments for the treatment of cancer - Google Patents

Medicaments for the treatment of cancer Download PDF

Info

Publication number: UA73748C2
Authority: UA; Ukraine
Prior art keywords: methyl; phenyl; dihydro; oxoquinoline; carboxamide
Prior art date: 1999-10-25

Application number

UA2002032524A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Active Biotech Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-25

Filing date

2000-10-24

Publication date

2005-09-15

1999-10-25 Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx

2000-10-24 Application filed by Active Biotech Ab filed Critical Active Biotech Ab

2005-09-15 Publication of UA73748C2 publication Critical patent/UA73748C2/uk

Links

238000011282 treatment Methods 0.000 title abstract description 12
206010028980 Neoplasm Diseases 0.000 title abstract description 9
239000003814 drug Substances 0.000 title abstract description 9
201000011510 cancer Diseases 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 abstract description 37
238000000034 method Methods 0.000 abstract description 13
230000003287 optical effect Effects 0.000 abstract description 4
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
238000004519 manufacturing process Methods 0.000 abstract description 3
230000008569 process Effects 0.000 abstract description 2
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
239000001257 hydrogen Substances 0.000 description 30
229910052739 hydrogen Inorganic materials 0.000 description 30
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
150000002431 hydrogen Chemical class 0.000 description 18
239000000203 mixture Substances 0.000 description 18
-1 methoxy, phenyl Chemical group 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
238000005481 NMR spectroscopy Methods 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
125000003118 aryl group Chemical group 0.000 description 15
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 15
239000000243 solution Substances 0.000 description 15
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 14
239000000460 chlorine Substances 0.000 description 14
229910052801 chlorine Inorganic materials 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 12
239000011737 fluorine Chemical group 0.000 description 12
229910052731 fluorine Inorganic materials 0.000 description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
239000000651 prodrug Substances 0.000 description 10
229940002612 prodrug Drugs 0.000 description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 10
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000002904 solvent Substances 0.000 description 9
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
229910052794 bromium Inorganic materials 0.000 description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000012074 organic phase Substances 0.000 description 7
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
238000003756 stirring Methods 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
239000002253 acid Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
239000013078 crystal Substances 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
235000017557 sodium bicarbonate Nutrition 0.000 description 5
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
241000408529 Libra Species 0.000 description 4
206010060862 Prostate cancer Diseases 0.000 description 4
208000000236 Prostatic Neoplasms Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
238000005917 acylation reaction Methods 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
238000007273 lactonization reaction Methods 0.000 description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
RULWBFLPUAFFGY-UHFFFAOYSA-N 2-(hydroxymethyl)benzamide Chemical class NC(=O)C1=CC=CC=C1CO RULWBFLPUAFFGY-UHFFFAOYSA-N 0.000 description 3
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000010933 acylation Effects 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
229960004679 doxorubicin Drugs 0.000 description 3
125000002587 enol group Chemical group 0.000 description 3
230000028709 inflammatory response Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
150000008064 anhydrides Chemical class 0.000 description 2
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
150000001767 cationic compounds Chemical class 0.000 description 2
125000004093 cyano group Chemical group *C#N 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
229960002887 deanol Drugs 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229910001411 inorganic cation Inorganic materials 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
150000002892 organic cations Chemical class 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
125000001302 tertiary amino group Chemical group 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000005951 type IV hypersensitivity Effects 0.000 description 2
208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
ACOQDKIUGAKZTC-UHFFFAOYSA-N 2,6-bis(dimethylamino)benzonitrile Chemical compound CN(C)C1=CC=CC(N(C)C)=C1C#N ACOQDKIUGAKZTC-UHFFFAOYSA-N 0.000 description 1
BNBRIFIJRKJGEI-UHFFFAOYSA-N 2,6-difluorobenzonitrile Chemical compound FC1=CC=CC(F)=C1C#N BNBRIFIJRKJGEI-UHFFFAOYSA-N 0.000 description 1
IBAGBHFAJNYENY-UHFFFAOYSA-N 2-(dimethylamino)-6-(methylamino)benzonitrile Chemical compound CNC1=CC=CC(N(C)C)=C1C#N IBAGBHFAJNYENY-UHFFFAOYSA-N 0.000 description 1
WWNKVUULRIWDJZ-UHFFFAOYSA-N 2-(dimethylamino)-6-fluorobenzonitrile Chemical compound CN(C)C1=CC=CC(F)=C1C#N WWNKVUULRIWDJZ-UHFFFAOYSA-N 0.000 description 1
IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
AMKPQMFZCBTTAT-UHFFFAOYSA-N 3-ethylaniline Chemical compound CCC1=CC=CC(N)=C1 AMKPQMFZCBTTAT-UHFFFAOYSA-N 0.000 description 1
WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
VFKZOVNOHFQLGN-UHFFFAOYSA-N 4-chloro-2-oxo-1h-quinoline-3-carboxamide Chemical compound C1=CC=C2NC(=O)C(C(=O)N)=C(Cl)C2=C1 VFKZOVNOHFQLGN-UHFFFAOYSA-N 0.000 description 1
HNHORERSXGGVDQ-UHFFFAOYSA-N 5-(dimethylamino)-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound CN1C(=O)C(C(O)=O)=C(O)C2=C1C=CC=C2N(C)C HNHORERSXGGVDQ-UHFFFAOYSA-N 0.000 description 1
FTBWKSJUFWRKGL-UHFFFAOYSA-N 5-chloro-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylic acid Chemical compound C1=CC(Cl)=C2C(O)=C(C(O)=O)C(=O)N(C)C2=C1 FTBWKSJUFWRKGL-UHFFFAOYSA-N 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241001397173 Kali <angiosperm> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000006069 Suzuki reaction reaction Methods 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
150000001448 anilines Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
238000011613 copenhagen rat Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
KFYPWXUWAUYKHF-UHFFFAOYSA-N ethyl 5-(dimethylamino)-4-hydroxy-1-methyl-2-oxoquinoline-3-carboxylate Chemical compound C1=CC=C2N(C)C(=O)C(C(=O)OCC)=C(O)C2=C1N(C)C KFYPWXUWAUYKHF-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
239000012634 fragment Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000011343 solid material Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000012058 sterile packaged powder Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000012360 testing method Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA2002032524A 1999-10-25 2000-10-24 Medicaments for the treatment of cancer UA73748C2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US16140799P	1999-10-25	1999-10-25
SE9903838A SE9903838D0 (sv)	1999-10-25	1999-10-25	Novel compounds
US21281600P	2000-06-21	2000-06-21
SE0002320A SE0002320D0 (sv)	1999-10-25	2000-06-21	Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en)	1999-10-25	2000-10-24	Drugs for the treatment of malignant tumours

Publications (1)

Publication Number	Publication Date
UA73748C2 true UA73748C2 (en)	2005-09-15

Family

ID=27484521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002032524A UA73748C2 (en)	1999-10-25	2000-10-24	Medicaments for the treatment of cancer

Country Status (21)

Country	Link
EP (1)	EP1224172B1 (de)
JP (1)	JP3950337B2 (de)
KR (2)	KR100674160B1 (de)
AT (1)	ATE358668T1 (de)
AU (1)	AU775057B2 (de)
CA (1)	CA2386775C (de)
CZ (1)	CZ298534B6 (de)
DE (1)	DE60034240T2 (de)
DK (1)	DK1224172T3 (de)
EE (1)	EE200200207A (de)
ES (1)	ES2280258T3 (de)
HK (1)	HK1049830A1 (de)
HR (1)	HRP20020353A2 (de)
HU (1)	HU229072B1 (de)
IL (2)	IL148782A0 (de)
IS (1)	IS2750B (de)
NO (1)	NO323320B1 (de)
NZ (1)	NZ518296A (de)
SE (1)	SE0002320D0 (de)
UA (1)	UA73748C2 (de)
WO (1)	WO2001030758A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) *	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
SE0401578D0 (sv) *	2004-06-18	2004-06-18	Active Biotech Ab	Novel compounds
CA2881078C (en)	2004-06-24	2018-10-02	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
BRPI0617477A2 (pt)	2005-10-19	2011-07-26	Teva Pharma	mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
LT1993360T (lt)	2005-12-28	2017-06-12	Vertex Pharmaceuticals Incorporated	N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
CN101466379B (zh)	2006-06-12	2012-10-31	泰华制药工业有限公司	稳定的拉喹莫德的制剂
KR100916160B1 (ko) *	2007-02-21	2009-09-08	(주)바이오버드	약제학적 항암 조성물
EP2065380A1 (de) *	2007-08-22	2009-06-03	F.Hoffmann-La Roche Ag	Pyridonamid-Derivate als Focal-Adhesion-Kinase (FAK) Hemmer und deren Verwendung zur Behandlung von Krebs
WO2009082471A1 (en)	2007-12-20	2009-07-02	Teva Pharmaceutical Industries, Ltd.	Stable laquinimod preparations
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
AU2009288108B2 (en)	2008-09-03	2013-10-17	Teva Pharmaceutical Industries, Ltd.	2-oxo-1,2-dihydro-quinoline modulators of immune function
SI3330255T1 (sl)	2009-03-20	2021-03-31	Vertex Pharmaceuticals Incorporated	Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
KR20130065728A (ko) *	2010-10-14	2013-06-19	임뮤나르 에이비	Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
EP2537517A1 (de) *	2011-06-22	2012-12-26	Active Biotech AB	Deuterium-angereichertes 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluor-methyl)phenyl]-1,2-dihydrochinolin-3-carboxamid
EP2819670B1 (de)	2012-02-27	2026-05-20	Vertex Pharmaceuticals Incorporated	Pharmazeutische zubereitung und deren verabreichungen
EA201590788A1 (ru) *	2012-11-07	2015-12-30	Тева Фармасьютикал Индастриз Лтд.	Аминные соли лахинимода
JP2016514162A (ja)	2013-03-14	2016-05-19	テバファーマシューティカルインダストリーズリミティド	ラキニモドナトリウムの結晶およびその製造のための改善された方法
EP3041472B1 (de) *	2014-09-23	2017-02-01	Active Biotech AB	Chinolincarboxamide zur verwendung bei der behandlung von multiplem myelom
CA2963945C (en)	2014-10-07	2023-01-10	Vertex Pharmaceuticals Incorporated	Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
BR112017009854B1 (pt) *	2014-11-19	2022-08-23	Active Biotech Ab	Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia
US11826363B2 (en)	2017-10-13	2023-11-28	Ono Pharmaceutical Co., Ltd.	Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
US12478621B2 (en) *	2019-11-28	2025-11-25	Deutsches Krebsforschungszentrum	Substituted aminoquinolones as dgkalpha inhibitors for immune activation
KR102978225B1 (ko)	2020-03-03	2026-06-15	액티브 바이오테크 에이비	조합 요법에 사용하기 위한 타스퀴니모드 또는 이의 약학적으로 허용가능한 염
JP2023527782A (ja) *	2020-05-21	2023-06-30	ステムシナジーセラピューティクス，インク．	Ｎｏｔｃｈ阻害剤及びその使用
WO2022152902A1 (en)	2021-01-18	2022-07-21	Active Biotech Ab	Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
KR20240012436A (ko) *	2021-05-25	2024-01-29	액티브 바이오테크 에이비	복수의 타스퀴니모드 입자 및 그 용도
CA3221689A1 (en)	2021-07-02	2023-01-05	Hans Wannman	A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
AR126963A1 (es)	2021-09-13	2023-12-06	Lilly Co Eli	Agonistas de ahr
TWI838849B (zh) *	2021-09-13	2024-04-11	美商美國禮來大藥廠	Ahr促效劑
CA3241699A1 (en) *	2021-12-20	2023-06-29	The Johns Hopkins University	Compounds for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE52670B1 (en) *	1981-03-03	1988-01-20	Leo Ab	Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) *	1991-04-22	1991-06-05	Fujisawa Pharmaceutical Co	Quinoline derivatives
GB9404378D0 (en) *	1994-03-07	1994-04-20	Fujisawa Pharmaceutical Co	Quinoline derivatives
GB2290786A (en) *	1994-06-30	1996-01-10	Fujisawa Pharmaceutical Co	Quinoline derivatives
SE9801474D0 (sv) *	1998-04-27	1998-04-27	Active Biotech Ab	Quinoline Derivatives
SE9802549D0 (sv) *	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
US6121287A (en) *	1998-07-15	2000-09-19	Active Biotech Ab	Quinoline derivatives
SE9802550D0 (sv) *	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives

2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active Expired - Fee Related
- 2000-10-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en not_active Ceased
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 EP EP00973329A patent/EP1224172B1/de not_active Expired - Lifetime
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active Expired - Fee Related
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU229072B1 (en)	2013-07-29
IL148782A0 (en)	2002-09-12
EP1224172A1 (de)	2002-07-24
DE60034240T2 (de)	2007-12-20
DE60034240D1 (de)	2007-05-16
NO20021932D0 (no)	2002-04-24
JP3950337B2 (ja)	2007-08-01
EE200200207A (et)	2003-06-16
SE0002320D0 (sv)	2000-06-21
KR100597938B1 (ko)	2006-07-06
HUP0203238A2 (hu)	2003-01-28
HUP0203238A3 (en)	2003-05-28
IS6329A (is)	2002-04-02
ES2280258T3 (es)	2007-09-16
KR20020043646A (ko)	2002-06-10
HRP20020353A2 (en)	2005-10-31
CA2386775C (en)	2004-07-13
EP1224172B1 (de)	2007-04-04
CA2386775A1 (en)	2001-05-03
CZ298534B6 (cs)	2007-10-31
NO323320B1 (no)	2007-03-12
JP2003512454A (ja)	2003-04-02
NZ518296A (en)	2003-06-30
KR20060054496A (ko)	2006-05-22
IL148782A (en)	2007-05-15
DK1224172T3 (da)	2007-08-13
KR100674160B1 (ko)	2007-01-24
IS2750B (is)	2011-08-15
ATE358668T1 (de)	2007-04-15
AU775057B2 (en)	2004-07-15
HK1049830A1 (zh)	2003-05-30
WO2001030758A1 (en)	2001-05-03
CZ20021293A3 (cs)	2002-07-17
AU1185101A (en)	2001-05-08
NO20021932L (no)	2002-06-21

Publication	Publication Date	Title
KR100597938B1 (ko)	2006-07-06	악성 종양의 치료용 약제
US6395750B1 (en)	2002-05-28	Drugs for the treatment of malignant tumors
AU553775B2 (en)	1986-07-24	(1-(2-benzoxazolyl)hydrazino)alkyl nitrile derivatives
KR20190026827A (ko)	2019-03-13	방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
WO2018157842A1 (zh)	2018-09-07	2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途
KR20150038363A (ko)	2015-04-08	지방산 아미드 가수분해효소 억제제로서 보론산 및 에스테르
CZ20003849A3 (cs)	2001-03-14	Deriváty chinolinu
CA2150162C (fr)	2002-05-14	Nouveau n-pyridyl carboxamides et derives, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2006301708B2 (en)	2011-06-23	Glycyrrhetinic acid-30-amide derivatives and the uses thereof
EP3006432B1 (de)	2017-11-15	2,3-butandiamid-epoxyverbindung und herstellungsverfahren und verwendung davon
RU2300532C2 (ru)	2007-06-10	Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
HU195486B (en)	1988-05-30	Process for preparing new pyridine derivatives
US20040267015A1 (en)	2004-12-30	Peptide deformylase inhibitors
CN104974108A (zh)	2015-10-14	一类2,2’-串联双噻唑类化合物及其制备方法和用途
RU2240313C2 (ru)	2004-11-20	Лекарственные средства для лечения злокачественных опухолей
RU2075477C1 (ru)	1997-03-20	1-//2-(динизший алкиламино)алкил/амино/-4-замещенные тиоксантен-9-оны и фармацевтическая композиция, обладающая противоопухолевой активностью
CN102260187B (zh)	2015-04-15	取代的氨甲酰基环己甲酸类化合物及其制法和用途
CN113735788B (zh)	2025-10-03	布洛芬三唑硫醇衍生物及其在制备新冠病毒抑制剂中应用
WO2016019588A1 (en)	2016-02-11	Oxacazone compounds to treat clostridium difficile
CH629194A5 (fr)	1982-04-15	Amino aryl triazines-1,2,4 utilisables dans le traitement d'algies diverses.
UA160042U (uk)	2025-07-30	Спосіб одержання 1,2,4-триазоловмісних похідних 1,4-нафтохінону, що виявляють протисудомну активність
US2762806A (en)	1956-09-11	2, 3-alkylenedioxy-6-nitro-9-aminoacridines and their synthesis
JPS6312870B2 (de)	1988-03-23
JPH0157114B2 (de)	1989-12-04
EP0075600A1 (de)	1983-04-06	2-thiazolamin abkömmlinge, verfahren zu deren herstellung, sowie arzneimittelzusammensetzung